B. Riley reiterated their buy rating on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) in a report issued on Monday morning, Marketbeat reports. B. Riley currently has a $20.00 price objective on the biotechnology company’s stock. B. Riley also issued estimates for Oramed Pharmaceuticals’ Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.28) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.53) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($2.10) EPS and FY2022 earnings at ($1.08) EPS.

Several other equities analysts also recently weighed in on ORMP. ValuEngine downgraded shares of Oramed Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, December 5th. HC Wainwright restated a buy rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a report on Wednesday, November 22nd.

Oramed Pharmaceuticals (NASDAQ:ORMP) opened at $8.61 on Monday. Oramed Pharmaceuticals has a twelve month low of $5.82 and a twelve month high of $11.34.

A number of large investors have recently bought and sold shares of ORMP. Wells Fargo & Company MN increased its holdings in Oramed Pharmaceuticals by 4.4% during the 2nd quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 625 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Oramed Pharmaceuticals during the 2nd quarter valued at about $125,000. Finally, Susquehanna International Group LLP purchased a new position in Oramed Pharmaceuticals during the 3rd quarter valued at about $185,000. Hedge funds and other institutional investors own 2.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/oramed-pharmaceuticals-ormp-earns-buy-rating-from-b-riley/1762861.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.